Javascript must be enabled to continue!
Increased expression of the TLR7/9 signaling pathways in chronic active EBV infection
View through CrossRef
We aimed to investigate the immunological mechanisms of the Toll-like receptor (TLR) signaling pathways in different types of Epstein-Barr virus (EBV) infection. We retrospectively summarized the clinical data, routine laboratory tests and the immunological function of the infectious mononucleosis (IM) and chronic active EBV infection (CAEBV) patients. A real-time quantitative PCR array was used to detect the mRNA expression levels of TLR7/TLR9 and myeloid-differentiation factor 88 (MyD88). Flow cytometry was used to detect the protein expression of TLR7/TLR9. The MyD88 and nuclear factor-κB (NF-κB) (p65) protein were detected by western blotting. A cytometric bead array (CBA) assay was used to detect the expression of downstream cytokines. CAEBV patients presented with increased expression of TLR7/TLR9 in monocytes and B lymphocytes. TLR9 expression in the B lymphocytes of IM patients was decreased compared with the CAEBV pateints. Downstream signaling mediators, including MyD88 and NF-κB, were revealed to be increased in EBV-infected patients. Moreover, the expression of MyD88 and NF-κB was higher in CAEBV patients, leading to disrupted balance of downstream cytokines. EBV may activate the immune system via TLR7/TLR9 signaling pathways. Moreover, the overactivated TLR7/TLR9 pathway in CAEBV patients resulted in excessive inflammation, which might be relevant to the poor prognosis.
Frontiers Media SA
Title: Increased expression of the TLR7/9 signaling pathways in chronic active EBV infection
Description:
We aimed to investigate the immunological mechanisms of the Toll-like receptor (TLR) signaling pathways in different types of Epstein-Barr virus (EBV) infection.
We retrospectively summarized the clinical data, routine laboratory tests and the immunological function of the infectious mononucleosis (IM) and chronic active EBV infection (CAEBV) patients.
A real-time quantitative PCR array was used to detect the mRNA expression levels of TLR7/TLR9 and myeloid-differentiation factor 88 (MyD88).
Flow cytometry was used to detect the protein expression of TLR7/TLR9.
The MyD88 and nuclear factor-κB (NF-κB) (p65) protein were detected by western blotting.
A cytometric bead array (CBA) assay was used to detect the expression of downstream cytokines.
CAEBV patients presented with increased expression of TLR7/TLR9 in monocytes and B lymphocytes.
TLR9 expression in the B lymphocytes of IM patients was decreased compared with the CAEBV pateints.
Downstream signaling mediators, including MyD88 and NF-κB, were revealed to be increased in EBV-infected patients.
Moreover, the expression of MyD88 and NF-κB was higher in CAEBV patients, leading to disrupted balance of downstream cytokines.
EBV may activate the immune system via TLR7/TLR9 signaling pathways.
Moreover, the overactivated TLR7/TLR9 pathway in CAEBV patients resulted in excessive inflammation, which might be relevant to the poor prognosis.
Related Results
Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction
Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction
ABSTRACTBackgroundAs a pattern recognition receptor, Toll‐like receptor 7 (TLR7) widely presented in the endosomal membrane of various cells. However, the precise role and mechanis...
The Nuclear Lamina Binds the EBV Genome During Latency and Regulates Viral Gene Expression
The Nuclear Lamina Binds the EBV Genome During Latency and Regulates Viral Gene Expression
ABSTRACTThe Epstein Barr virus (EBV) infects almost 95% of the population worldwide. While typically asymptomatic, EBV latent infection is associated with several malignancies of e...
Risk factors for post‐transplant Epstein‐Barr virus events in pediatric recipients of hematopoietic stem cell transplants
Risk factors for post‐transplant Epstein‐Barr virus events in pediatric recipients of hematopoietic stem cell transplants
AbstractBackgroundEpstein‐Barr virus (EBV) can cause severe disease following hematopoietic stem cell transplant (HSCT), including post‐transplant lymphoproliferative disorder (PTL...
Abstract 3749: Oncogenic role of Epstein-Barr virus lnc-BARTs in EBV associated tumors
Abstract 3749: Oncogenic role of Epstein-Barr virus lnc-BARTs in EBV associated tumors
Abstract
While majority of humans infected with Epstein-Barr virus (EBV) is asymptomatic for whole life, EBV is found to associate with several human cancers, includ...
Abstract 3500: Epstein-Barr virus BART noncoding RNAs modulate host gene expression for virus latency leading to oncogenesis in epithelial cells
Abstract 3500: Epstein-Barr virus BART noncoding RNAs modulate host gene expression for virus latency leading to oncogenesis in epithelial cells
Abstract
Epstein-Barr virus (EBV) efficiently establishes and maintains a state of latency in resting B cells, with persistent asymptomatic infections occurring in m...
Case–Control Analysis of 48 Pediatric Infection-Associated Hemophagocytic Lymphohistiocytosis
Case–Control Analysis of 48 Pediatric Infection-Associated Hemophagocytic Lymphohistiocytosis
Abstract
Objective
To analyze the clinical characteristics, laboratory data and treatment plan of hemophagocytic lymphohistiocytosis (HLH).
...
Transfusion‐related Epstein‐Barr virus (EBV) infection: A multicenter prospective cohort study among pediatric recipients of hematopoietic stem cell transplants (TREASuRE study)
Transfusion‐related Epstein‐Barr virus (EBV) infection: A multicenter prospective cohort study among pediatric recipients of hematopoietic stem cell transplants (TREASuRE study)
AbstractBackgroundEpstein‐Barr virus (EBV) is carried in the blood of most adults, and transfusion‐related infections have been reported. EBV is particularly deleterious in immunos...
Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines
Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines
AbstractAlthough glycoconjugate vaccines are generally very efficacious, there is still a need to improve their efficacy, especially in eliciting a strong primary antibody response...

